Yale Secret Shopper Study Finds 92% of Online Websites Prescribe GLP-1 Drugs With Minimal Clinician Oversight
Key Insights
A Yale study published in JAMA found that 92% of 49 online websites prescribed GLP-1 medications to a fictitious patient profile, with 69% shipping the drugs directly.
Most websites sold compounded GLP-1 versions not FDA-reviewed or clinically tested, raising significant safety concerns about unregulated mass-marketed medications.
Researchers found prescriptions were often approved without any direct clinician communication, bypassing essential risk-benefit discussions and medical history verification.
A Yale School of Medicine research team has published startling findings revealing that the vast majority of online websites readily prescribe GLP-1 receptor agonists (search) with minimal clinical oversight, raising serious concerns about patient safety in the rapidly expanding direct-to-consumer telehealth market. The study, published in JAMA on July 6, 2026, found that 92% of 49 websites surveyed prescribed a GLP-1 medication to a fictitious patient profile, and 69% mailed the drug directly.
"We knew many people were accessing these drugs outside of insurance coverage, but we were surprised that the vast majority of these websites did not require communication with a clinician," said first-author Ashwin Chetty, a fourth-year medical student at Yale School of Medicine. "In some cases, the request was put in on a Monday evening, approved shortly after, and the prescription was delivered by Tuesday or Wednesday."
Study Design and Alarming Findings
The researchers created a patient profile of a 27-year-old male who qualified for a GLP-1 receptor agonist and attempted to obtain a prescription through 49 different websites. The results were striking: nearly all platforms approved the prescription, and a substantial majority shipped the medication, often within days and without any direct interaction with a prescribing clinician.
The study demonstrates that if an eligible patient is able to pay for the medication, they will receive it quickly and with very little oversight, according to senior author Reshma Ramachandran, MD, MHS, assistant professor of medicine in the division of general medicine at Yale.
Compounded Medications: An Unregulated Market
Most of the companies in the secret shopper study sold compounded versions of GLP-1 medications, which are not regulated by the U.S. Food and Drug Administration (FDA) and are therefore more affordable. These products exist outside the standard drug approval framework.
"These compounded products have never reached a clinical trial, and they've had no FDA review. The companies are creating new drugs and selling them across state lines. It's alarming that these medications—which have not been tested on patients—are being mass-produced and mass-marketed for profit," said Ramachandran.
The researchers emphasized that consumers may not be aware of the possible safety risks associated with obtaining these medications through an insecure supply chain.
Absence of Patient-Clinician Relationship
A particularly concerning finding was that in most cases, the secret shopper was able to access a prescription without talking to a clinician to verify the provided information. Since even FDA-approved medications carry risks, standard clinical practice involves discussions about risks and benefits, including contraindications such as other diseases or drugs that may interact adversely.
"There are certain medical conditions that are important to discuss when deciding whether or not a patient should be on a GLP-1," said Chetty. "And so I would have expected that, in light of this, there would be a more thorough medical history where more questions were asked to ensure all bases are covered, which wasn't the case for many of these websites."
Ramachandran added: "Every drug that we prescribe for our patients has some sort of risk-benefit that's personalized to each person."
Call for Regulatory Safeguards
Various medical professional societies have issued clear guidelines and best practices for prescribing GLP-1 receptor agonists (search). The researchers argue that online platforms must align their practices with these standards.
"The websites need to have protections in place that are more robust than simply a clinician who's just willing to prescribe. Companies and organizations need to follow the guidelines by asking the correct questions and ensuring they're prescribing medications appropriately," Ramachandran said.
The research team calls for greater levels of patient protection through increased regulation and requirements that websites disclose the risks of taking compounded drugs.
"As we're seeing telehealth platforms grow across the country, and replacing in-person healthcare access, telehealth needs to replicate the patient-clinician experience that happens in the real-world. It can't just be a pay-to-prescribe sort of platform. It needs to be a pay-for-appropriate-treatment platform," said Ramachandran.
Other authors of the study include Alissa Chen, MD, MPH, and Joseph Ross, MD, MHS.